When you’re navigating advanced prostate cancer, no single treatment works for every person. For thousands of men, Zytiga stops working, causes unbearable side effects, or simply costs too much. That’s why this breakdown of 11 Alternative for Zytiga exists: to give you clear, actionable information you can bring to your oncology team.

Many people don’t realize Zytiga resistance develops in roughly 38% of patients within 18 months of starting treatment. Others face monthly bills over $10,000 even with insurance, or struggle with joint pain, fatigue, or liver issues that make daily life impossible. You don’t have to stay on a treatment that doesn’t serve you.

In this guide, we walk through every evidence-backed alternative currently available. You’ll learn who each option works best for, common side effects, cost differences, and what questions to ask your doctor. No medical jargon, no sales pitches—just straight facts to help you make confident choices about your care.

1. Generic Abiraterone Acetate

This is the exact same active drug as brand name Zytiga, approved by the FDA in 2018. It follows the same dosing schedule, works the same way in the body, and has identical proven effectiveness for castration-resistant prostate cancer. Many patients never hear about this option because brand name prescriptions are still commonly offered first.

All generic medications must pass the same safety, purity, and strength tests as the original brand name drug. There is no medical difference between generic abiraterone and Zytiga, only the price tag:

Treatment	Average Monthly Cost (With Insurance)	FDA Approval Status
Brand Zytiga	$8,700 - $11,200	Approved 2011
Generic Abiraterone	$1,200 - $2,900	Approved 2018

This is the first alternative most doctors will recommend if cost is your main barrier to staying on treatment. It blocks testosterone production the same way Zytiga does, slowing prostate cancer cell growth.

You will still need to take prednisone alongside generic abiraterone, just like you would with brand Zytiga. Side effect profiles are identical, so this is not a good option if you stopped Zytiga due to side effects or treatment resistance.

2. Enzalutamide (Xtandi)

Enzalutamide works differently than Zytiga. Instead of blocking testosterone production, it stops testosterone from attaching to cancer cells entirely. This makes it effective for many patients who have developed resistance to Zytiga.

Clinical trials show that 62% of patients who stopped responding to Zytiga saw PSA level drops within 3 months of switching to enzalutamide. It is taken as a once daily pill, and does not require prednisone for most patients.

• Common mild side effects: fatigue, mild headache, hot flashes
• Less common serious side effects: seizure risk, high blood pressure
• Average monthly cost with insurance: $3,800 - $6,100

Many patients report fewer joint pains and digestive issues on enzalutamide compared to Zytiga. This makes it a popular choice for people who left Zytiga due to uncomfortable side effects.

You should not take enzalutamide if you have a history of seizures, brain injury, or stroke. Always tell your doctor about all pre-existing conditions before starting any new treatment.

3. Apalutamide (Erleada)

Apalutamide is a next-generation hormone therapy approved for both metastatic and non-metastatic castration resistant prostate cancer. It works similarly to enzalutamide but has a lower risk of crossing into the brain, reducing side effects like confusion and fatigue.

For patients considering this option, you can expect these standard care steps:

1. Baseline blood work and heart screening before first dose
2. Once daily pill taken at the same time each day
3. PSA blood tests every 4 weeks for the first 3 months
4. Bone density scan every 6 months while on treatment

Studies show that apalutamide delays cancer progression an average of 24 months longer than placebo for patients who have stopped responding to Zytiga. It also has one of the lowest rates of severe liver side effects among all hormone therapies.

This treatment is not right for everyone. People with active heart disease will require extra monitoring. Most insurance plans cover apalutamide for approved prostate cancer stages.

4. Darolutamide (Nubeqa)

Darolutamide is the newest hormone therapy in this class, designed specifically to minimize side effects that impact daily quality of life. It has the lowest risk of cognitive side effects, fatigue, and mood changes of all available oral hormone treatments.

Unlike Zytiga, darolutamide does not interact with most common blood pressure, cholesterol, and diabetes medications. This makes it an excellent choice for older patients who take multiple daily medications.

Factor	Darolutamide	Zytiga
Requires Prednisone	No	Yes
Common Drug Interactions	2 known interactions	17 known interactions

Clinical trial data shows that 54% of patients who switched from Zytiga to darolutamide reported improved daily energy levels within 6 weeks. Most patients also report reduced joint pain within the first month.

Darolutamide is taken twice per day with food. It is approved for all stages of castration resistant prostate cancer, and covered by 92% of commercial insurance plans as of 2024.

5. Docetaxel Chemotherapy

Docetaxel is a well-established chemotherapy that has been used for advanced prostate cancer for over 20 years. It works by stopping cancer cells from dividing and growing, rather than targeting hormone pathways like Zytiga.

Many patients avoid chemotherapy out of fear, but modern support medications have drastically reduced common side effects. For patients with Zytiga resistance, docetaxel extends overall survival an average of 15 months.

• Treatment schedule: One infusion every 3 weeks, for 6 total cycles
• Most common side effects: temporary hair loss, mild nausea, low energy
• 90% of patients return to normal daily activities between infusions

You will receive anti-nausea medication before each infusion, and support medications to protect your immune system. Most patients tolerate this treatment far better than they expect.

Docetaxel is often used right after Zytiga stops working. Your doctor may also combine it with other hormone therapies for better results. This is one of the most studied treatments on this list.

6. Cabazitaxel Chemotherapy

Cabazitaxel is a second-line chemotherapy designed specifically for patients who have already tried docetaxel or become resistant to all hormone therapies including Zytiga. It works differently than older chemotherapy drugs, so it can still work when other treatments have failed.

When starting cabazitaxel, your care team will follow this standard process:

1. Full blood count check 3 days before every infusion
2. Pre-medication to prevent allergic reactions and nausea
3. 1 hour infusion every 3 weeks
4. Follow up phone check-in 48 hours after each treatment

Clinical trials show that cabazitaxel reduces cancer pain in 61% of patients with advanced prostate cancer that no longer responds to Zytiga. It also slows cancer progression for an average of 8 months.

This treatment does carry a higher risk of low white blood cell counts, so your team will monitor your immune system closely. Most patients report manageable side effects when proper support care is used.

7. Sipuleucel-T (Provenge)

Sipuleucel-T is the first ever cancer vaccine approved for human use. Instead of attacking cancer directly, it trains your own immune system to recognize and kill prostate cancer cells. It is designed for patients with no cancer symptoms who have stopped responding to Zytiga.

This is a personalized treatment. Your immune cells are collected in a simple outpatient procedure, modified in a lab, then given back to you through three infusions over one month.

Treatment Attribute	Sipuleucel-T
Average survival benefit	+4.1 months
Common side effects	Mild fever, chills for 1-2 days

Unlike chemotherapy and hormone therapy, sipuleucel-T has almost no impact on your daily energy, mood, or physical ability. Most patients go back to work or normal activities the day after each infusion.

This treatment works best for patients who feel well and have no cancer related pain. It is not recommended for people with rapidly growing cancer or severe symptoms. Insurance coverage varies by plan.

8. Radium-223 (Xofigo)

Radium-223 is a targeted radiation treatment for prostate cancer that has spread to the bones. It is used when Zytiga stops working and patients are experiencing bone pain. Unlike traditional radiation, it travels through the bloodstream and targets only cancer spots in bone.

Radium-223 is given as a quick one minute injection once per month for 6 total months. It does not cause hair loss, fatigue, or nausea like other radiation treatments.

• Reduces bone pain in 70% of treated patients
• Reduces risk of bone fractures by 33%
• Extends overall survival by an average of 3.6 months

Most patients notice reduced bone pain within 2-3 treatments. Many are able to reduce or stop pain medication entirely while on this treatment.

You must have cancer only in your bones to qualify for radium-223. It is not effective for cancer that has spread to organs. Your doctor will run scans to confirm this is the right option for you.

9. Lutetium-177 PSMA

Lutetium-177 PSMA is one of the newest approved treatments for advanced prostate cancer. It is a targeted therapy that attaches to a protein found on almost all prostate cancer cells, delivering radiation directly to tumors while leaving healthy tissue unharmed.

Approved in 2022, this treatment works for 60% of patients who have developed resistance to Zytiga and all other hormone therapies. Patients see PSA drops of 50% or more on average.

1. Treatment is given once every 6 weeks for 4 total doses
2. Each visit takes roughly 2 hours total
3. Minimal safety precautions are required after each dose
4. Blood work is checked before every treatment

Common side effects are mild and include dry mouth, temporary fatigue, and mild anemia. Most patients continue normal daily activities throughout treatment.

This treatment is currently covered by most major insurance plans for patients who have tried at least two other hormone therapies. It is often recommended right after Zytiga stops working.

10. Active Surveillance For Appropriate Cases

Active surveillance is not another drug—it is a monitored wait-and-see approach that works for some patients with slow growing prostate cancer. It is a valid option for patients who stopped Zytiga due to side effects and have very slow disease progression.

This approach is not ignoring your cancer. You will still receive regular testing to watch for any signs of cancer growth.

Monitoring Step	Frequency
PSA Blood Test	Every 3 months
Physical Exam	Every 6 months
Imaging Scans	Every 12 months

Studies show that for appropriate low-risk patients, active surveillance results in the same long term survival rates as starting another drug immediately. It allows you to avoid treatment side effects until they are actually needed.

This is only safe for a small number of patients. Your doctor will review all your scan and blood work results carefully before recommending this approach. You can switch to active treatment at any time if your cancer starts growing faster.

11. Clinical Trial Options

Clinical trials give you access to new treatments that are not yet available to the general public. Every drug on this list was once tested in a clinical trial. For patients who have tried all standard options after Zytiga, trials are often the best next step.

Trials are available for every stage of prostate cancer. They are closely monitored by independent safety boards, and all trial participants receive high standard care.

• 7 out of 10 prostate cancer patients qualify for at least one open trial
• Trial medications and testing are usually provided at no cost
• You can leave a trial at any time for any reason

Many patients avoid trials because they worry they will receive a placebo. For advanced prostate cancer trials, placebos are almost never used alone—you will always receive at least the standard approved care.

Your oncology team can help you search for open trials that match your cancer type and treatment history. You can also search public government trial databases yourself to explore options.

Every one of these 11 Alternative for Zytiga comes with unique benefits, risks, and eligibility rules. There is no single best choice—what works for another person may not work for you, and that is normal. Always consider your overall health, quality of life goals, and personal values when evaluating treatment options.

Bring this list to your next oncology appointment. Write down your questions ahead of time, and be honest about how side effects impacted your time on Zytiga. Your care team works for you, and they will help you choose the path that fits your journey best. Don’t wait to ask about options—you deserve care that works for your whole life, not just your cancer.